Patent cliffs don’t just hit revenue—they hit supply chains.
When a blockbuster drug’s patent expires, the market doesn’t simply “get cheaper.” It gets messier: new entrants, shifting pricing dynamics, changing lead times, evolving regulatory pathway…

Generic drug companies are facing a quiet squeeze—and it’s not just about pricing. It’s about survival math.
For years, the generic model was straightforward: win approvals, scale manufacturing, compete on cost, and let volume do the heavy lifting. But…

Branded pharma’s revenue model is under siege—and the threats aren’t subtle.
In a recent piece, DrugPatentWatch lays out eight “brutal problems” that are quietly (and sometimes loudly) eroding the economics of branded drug companies. The headline takea…

Generic drug competition isn’t won in the lab—it’s won in the filing. And nowhere is that more obvious than in the FDA’s Orange Book, where the “time and win” playbook for market entry is quietly written.
If you’ve ever wondered how generic manufacture…

Biopharma is hiring for “IP,” but too many teams still treat IP like a silo—something you hand to legal after the strategy is set.
The result? Valuable knowledge gets trapped in decks, job descriptions stay vague, and portfolios don’t translate into or…

The Generic Cliff Doesn’t Arrive—It’s Engineered Around.
If you’ve ever wondered why some pharma companies seem to “beat” expiring patents while others get hit with a sudden revenue drop, the answer is rarely luck. It’s strategy—often executed years …

Drug companies don’t just “get patents.” They build ecosystems.
That’s the uncomfortable truth behind how patent thickets form around biologic blockbusters—and why the fight over access, pricing, and innovation is increasingly a fight over patent str…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already spent the money—after the investment, after the deal, after the launch plan is locked. But in pharma, w…

Most teams hunt patents too late. Formulation patents reward earlier thinking.
In pharma, the race isn’t only about what a drug does—it’s about how it’s made, stabilized, delivered, and protected. And that’s exactly where formulation patents quietly ch…

Russia’s latest VED/SSM list update is a reminder that “generic timing” isn’t just a legal exercise—it’s an intelligence game.
If you’re a brand team, you’re watching for signals that competitors are lining up their launch calendars. If you’re a generi…